Malignant Melanocytic Tumors

Mathilde Kaspi, Thibaud Garcin, Cyril Habougit, Fabien Forest, Elisa Cinotti, and Jean-Luc Perrot

Contents

9.1	Lentigo Maligna	69
9.2	Melanoma	72

Abbreviations

AbAntibodiesHESHematoxylin-eosin-saffron stainIVCMIn vivo reflectance confocal microscopy

C. Habougit · F. Forest Department of Pathology, University Hospital of Saint-Etienne, Saint-Etienne Cedex 2, France e-mail: cyril.habougit@chu-st-etienne.fr; fabien.forest@chu-st-etienne.fr

E. Cinotti

Department of Dermatology, University of Siena, S. Maria alle Scotte Hospital, Siena, Italy e-mail: elisa.cinotti@unisi.it

J.-L. Perrot

Department of Dermatology, University Hospital of Saint-Etienne, Saint-Etienne Cedex 2, France e-mail: j.luc.perrot@chu-st-etienne.fr

© Springer Nature Switzerland AG 2020 M. Kaspi et al. (eds.), *Eyelid and Conjunctival Tumors*, https://doi.org/10.1007/978-3-030-36606-3_9

9.1 Lentigo Maligna

Lentigo maligna occurs in photo-exposed areas. Atypical melanocytes proliferate along the basement membrane without crossing it: lentigo maligna is a melanoma in situ. When melanocytes cross the basement membrane and invade the dermis the tumor is called lentigo maligna melanoma.

Clinically, lentigo maligna (Fig. 9.1) presents as a nonhomogeneous pigmented macule on sunexposed skin, with irregular contours.



Fig. 9.1 Clinical aspect of actinic lentigo





M. Kaspi (🖂) · T. Garcin

Department of Ophthalmology, University Hospital of Saint-Etienne, Saint-Etienne Cedex 2, France e-mail: mathilde.kaspi@gmail.com; garcinthibaud@gmail.com

The IVCM features are as follows (Fig. 9.2a–d):

- Relatively well-preserved epidermis with regular honeycomb pattern (not shown here)
- Atypical roundish and/or dendritic cells (that correspond to large cells of different shapes and sizes) at the dermo-epidermal junction (*orange stars*) and the suprabasal layers of the epidermis (pagetoid cells; *blue arrows*)



Fig. 9.2 IVCM features of actinic lentigo (a–d)

On optical microscopy the histologic features are as follows (Fig. 9.3e–i):

- At low magnification (e, f), melanocytic proliferation (*red dotted line*) occurs along the basement membrane, without crossing it.
- Melanocytes are marked in red in immunohistochemistry by the anti-Melan-A antibody (g).
- At high magnification (h, i), atypical melanocytes proliferate along the basement membrane in a lentiginous mode (*black circle*). Some nests at the level of the basement membrane are visible (*blue arrows*).



Fig. 9.3 Histological features of actinic lentigo (e-i). $(e, f) \times 100$ HES. $(g) \times 100$ Anti-Melan-A Ab. $(h, i) \times 200$ HES

9.2 Melanoma

Eyelid melanomas represent less than 1% of palpebral malignant tumors. In melanoma, atypical melanocytes are present in the epidermis and dermis. The most frequent histological types of palpebral melanomas are:

- Superficial spreading melanoma (SMM)
- Lentigo malignant melanoma (LMM)

The clinical aspect (Fig. 9.4) of this eyelid melanoma is a heterogeneous and irregular dark brown pigmentation.

The IVCM features are as follows (Fig. 9.5a–e):

- Disarranged epithelium (a–c) with large hyperreflective dendritric (*red circle*) and roundish pagetoid cells (*yellow arrows* and *image c*)
- Large hyperreflective polymorphic cells (*orange stars*) in the superficial dermis (d, e) in case of invasive melanoma

On optical microscopy the histologic features are as follows (Fig. 9.6f–k):

 At low magnification (f-i), melanocytic proliferation invades the dermis (*black circle*),



Fig. 9.4 Clinical aspect of eyelid melanoma

and its intraepidermal lateral component looks lentiginous (*blue dotted lines*). Melanocytes are stained in red by anti-Melan-A antibody.

At high magnification (j, k), the dermal component is composed of melanocytes arranged in nests (*green diamonds*). The intraepidermal lateral component is lentiginous (*blue dotted line*). Some mitoses are visible (*black arrows*).



Fig. 9.5 IVCM features of eyelid melanoma (a-e)



 $\label{eq:Fig.9.6} \textit{Fig. 9.6} \hspace{0.1 cm} \textit{Histological features of eyelid melanoma} (f-k). (f, g) \times 50 \hspace{0.1 cm} \textit{HES.} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, i) \times 50 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 200 \hspace{0.1 cm} \textit{HES} (h, k) \times 200 \hspace{0.1 cm} \textit{Anti-Melan-A Ab.} (j, k) \times 2$